Last but not least, Bcl-2/Bcl-xl inhibitors such as ABT-263 and ABT-737 have synergistic interaction with PPI in gastric cancer cells in both pH 7.4 and pH 6.5 conditions, which has a broad prospect in the field of cancer treatment. The gene discussed is BCL2; the disease is cancer.